See more : RTL Group S.A. (RTL.SW) Income Statement Analysis – Financial Results
Complete financial analysis of Kura Oncology, Inc. (KURA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kura Oncology, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Ilika plc (IKA.L) Income Statement Analysis – Financial Results
- Demae-Can Co.,Ltd (YUMSF) Income Statement Analysis – Financial Results
- Riverine China Holdings Limited (1417.HK) Income Statement Analysis – Financial Results
- PT Centratama Telekomunikasi Indonesia Tbk (CENT.JK) Income Statement Analysis – Financial Results
- Jiangsu Jiangnan High Polymer Fiber Co.,Ltd (600527.SS) Income Statement Analysis – Financial Results
Kura Oncology, Inc. (KURA)
About Kura Oncology, Inc.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 849.00K | 759.00K | 558.00K | 194.00K | 0.00 | 10.00K | 30.00K | 31.00K | 20.00K | 23.91K | 22.73K | 22.34K | 23.44K | 20.51K | 19.16K | 0.00 |
| Gross Profit | -849.00K | -759.00K | -558.00K | -194.00K | 0.00 | -10.00K | -30.00K | -31.00K | -20.00K | -23.91K | -22.73K | -22.34K | -23.44K | -20.51K | -19.16K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 115.24M | 92.81M | 84.72M | 60.40M | 47.83M | 46.79M | 26.43M | 20.40M | 17.78M | 8.05M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 50.57M | 47.05M | 46.54M | 31.50M | 19.65M | 16.10M | 9.65M | 7.96M | 6.09M | 3.85M | 22.34K | 23.44K | 20.51K | 20.51K | 19.16K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 50.57M | 47.05M | 46.54M | 31.50M | 19.65M | 16.10M | 9.65M | 7.96M | 6.09M | 3.85M | 22.34K | 23.44K | 20.51K | 20.51K | 19.16K | 0.00 |
| Other Expenses | 0.00 | 4.03M | 792.00K | 2.27M | 4.34M | 2.44M | 643.00K | 807.00K | 1.24M | 2.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -33.62K |
| Operating Expenses | 165.80M | 139.87M | 131.26M | 91.90M | 67.48M | 62.88M | 36.08M | 28.37M | 23.87M | 10.90M | 22.34K | 23.44K | 20.51K | 20.51K | 19.16K | -33.62K |
| Cost & Expenses | 165.80M | 139.87M | 131.26M | 91.90M | 67.48M | 62.88M | 36.08M | 28.37M | 23.87M | 10.90M | 22.34K | 23.44K | 20.51K | 41.02K | 38.32K | -33.62K |
| Interest Income | 14.72M | 4.25M | 1.21M | 2.80M | 4.67M | 3.17M | 751.00K | 499.00K | 128.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.55M | 229.00K | 414.00K | 578.00K | 580.00K | 970.00K | 888.00K | 577.00K | 88.00K | 5.88K | 4.97K | 3.60K | 1.89K | 1.89K | 838.00 | 0.00 |
| Depreciation & Amortization | 849.00K | 759.00K | 558.00K | 194.00K | 10.00K | 10.00K | 30.00K | 31.00K | 20.00K | 3.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -164.96M | -139.11M | -129.71M | -91.71M | -67.48M | -62.87M | -36.05M | -28.34M | -23.85M | -11.80M | -22.34K | -23.44K | -20.51K | -41.02K | -38.32K | -33.62K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -165.80M | -140.62M | -131.82M | -92.09M | -67.48M | -62.88M | -36.08M | -28.37M | -23.87M | -11.80M | -22.34K | -23.44K | -20.51K | -41.02K | -38.32K | -33.62K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 13.17M | 4.03M | 792.00K | 2.27M | 4.44M | 2.64M | 943.00K | 807.00K | 972.00K | 879.00K | 16.86K | 17.37K | 19.84K | 18.62K | 18.32K | 0.00 |
| Income Before Tax | -152.63M | -135.84M | -130.47M | -89.63M | -63.14M | -60.45M | -35.43M | -27.56M | -22.63M | -11.01M | -27.32K | -27.04K | -22.40K | -22.40K | -20.00K | -33.62K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 229.00K | -558.00K | -194.00K | -10.00 | 3.41M | -30.00K | -31.00K | -20.00K | 268.88K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -152.63M | -136.07M | -129.91M | -89.43M | -63.14M | -60.45M | -35.43M | -27.56M | -22.63M | -11.01M | -27.32K | -27.04K | -22.40K | -22.40K | -20.00K | -33.62K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.08 | -2.03 | -1.96 | -1.68 | -1.51 | -1.72 | -1.52 | -1.47 | -2.28 | -78.11 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -2.08 | -2.03 | -1.96 | -1.68 | -1.51 | -1.72 | -1.52 | -1.47 | -2.28 | -78.11 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 73.23M | 66.99M | 66.35M | 53.08M | 41.95M | 35.19M | 23.24M | 18.70M | 9.93M | 141.00K | 5.00M | 5.00M | 5.00M | 5.00M | 5.00M | 0.00 |
| Weighted Avg Shares Out (Dil) | 73.23M | 66.99M | 66.35M | 53.08M | 41.95M | 35.19M | 23.24M | 18.70M | 9.93M | 141.00K | 5.00M | 5.00M | 5.00M | 5.00M | 5.00M | 0.00 |
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on April 1, 2024, the...
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma
– Company anticipates dosing of KO-2806 in combination with adagrasib in KRASG12C-mutant NSCLC next quarter –
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on March 1, 2024, the...
Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
– Positive preliminary combination data from KOMET-007 trial of ziftomenib in NPM1-m and KMT2A-r AML, including effective mitigation of differentiation syndrome –
Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia
– KOMET-008 is evaluating ziftomenib in combination with gilteritinib, FLAG-IDA or LDAC in patients with relapsed/refractory NPM1-mutant or KMT2A-rearranged AML –
Kura Oncology to Participate in Three Upcoming Investor Conferences
SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief...
Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results
SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full...
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on February 1, 2024, the...
Kura Oncology stock jumped another 20% on Tuesday: here's why
Kura Oncology Inc (NASDAQ: KURA) rallied close to 20% this morning after reporting positive preliminary data for a Phase 1 study of its Ziftomenib “in combination with standards of care”. Ziftomenib trial pushes Kura Oncology stock up The dose-escalation trial...
Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia
– No differentiation syndrome events reported – – 100% CR rate with 7+3 in newly diagnosed NPM1-m and KMT2A-r AML – – 56% CR/CRh with ven/aza in menin inhibitor naïve patients with R/R AML – – 80% of patients remain...
Source: https://incomestatements.info
Category: Stock Reports